Blockade of CD86 ameliorates Leishmania major infection by down- regulating the Th2 response

Journal of Infectious Diseases

Volumn 174, Issue 6, 1996, Pages 1303-1308

  Brown, Julia A ^b   Titus, Richard G ^b   Nabavi, Nasrin ^b   Glimcher, Laurie H ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOKINE;

ALLERGIC ENCEPHALITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL POLARITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMOCYTE;

EID: 0029807762     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.6.1303     Document Type: Article

References (30)

1. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules differentially activate the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-18.
2. Corry DB, Reiner SL, Linsley PS, Locksley RM. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J Immunol 1994;153:4142-8.
3. Freeman GJ, Boussiotis VA, Anumanthan A, et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995;2:523-32.
4. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995;181:1145-55.
5. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995;2:555-9.
6. Thompson CB. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 1995;81:979-82.
7. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-77.
8. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA 1991;88:7011-5.
9. + cells correlate with resolution of lesions in murine cutaneous leishmaniasis. J Immunol 1992;149:2715-21.
10. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon-γ or interleukin 4 during the resolution or progression of murine leishmaniases. J Exp Med 1989;169:59-72.
11. + T cells during initiation of infection. J Exp Med 1994;179:447-56.
12. Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS. Locksley RM. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-dependent mechanism. J Exp Med 1990;171:115-27.
13. Chatelain R, Varkila K, Coffman RL. IL-4 induces a Th2 response in Leishmania major-infected mice. J Immunol 1992;148:1182-7.
14. + effector cells default to the Th2 pathway in interferon γ-deficient mice infected with Leishmania major. J Exp Med 1994;179:1367-71.
15. Tobin JF, Reiner SL, Hatam F, et al. Transfected Leishmania expressing biologically active IFN-γ. J Immunol 1993;150:5059-69.
16. Chakkalath HR, Titus RG. Leishmania major-parasitized macrophages augment Th2-type cell activation. J Immunol 1994;153:4378-87.
17. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-9.
18. Chen C, Faherty DA, Gault A, et al. Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. J Immunol 1994;152:2105-14.
19. Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM, Glimcher LH. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992;360:266-8.
20. Radka SF, Kostyu DD, Amos DB. A monoclonal antibody directed against the HLA-Bw6 epitope. J Immunol 1982;128:2804-6.
21. Marchand M, Daoud S, Titus RG, Louis L, Boon T. Variants with reduced virulence derived from Leishmania major after mutagen treatment. Parasite Immunol 1987;9:81-92.
22. Titus RG, Marchand M, Boon T, Louis JA. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 1985;7:545-55.
23. 22a.Taswell C. Limiting dilution assays for the separation, characterization and quantitation of biologically active particles and their clonal progeny. In: Pretlow TG, Pretlow TP, eds. Cell separation: methods and selected applications. New York: Academic Press, 1996:109-45.
24. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. J Immunol 1981;126:1614-9.
25. Abehsira-Amar O, Gibert M, Joliy M, Theze J, Jankovic DL. IL-4 plays a dominant role in the differential development of Tho into Th1 and Th2 cells. J Immunol 1992;148:3820-9.
26. + T cells from T cell receptor transgenic mice. J Exp Med 1992;176:1091-8.
27. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-9.
28. Wang ZE, Zheng S, Cony DB, et al. Interferon γ-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci USA 1994;91:12932-6.
29. Heinzel FP, Rerko RM, Ahmed F, Pearlman E. Endogenous IL-12 required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol 1995;155:730-9.
30. + T cell response. J Exp Med 1995;181:961-71.